Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program.

Abstract:

BACKGROUND:SCH 727965 is a novel drug in clinical development that potently and selectively inhibits CDK1, CDK2, CDK5, and CDK9. The activity of SCH 727965 was evaluated against the PPTP's in vitro and in vivo panels. PROCEDURES:SCH 727965 was tested against the PPTP in vitro panel using 96 hours exposure at concentrations ranging from 0.1 nM to 1.0 µM. It was tested against the PPTP in vivo panels at a dose of 40 mg/kg administered intraperitoneally twice weekly for 2 weeks and repeated at Day 21 with a total observation period of 6 weeks. RESULTS:The median IC(50) value for the cell lines was 7.5 nM, with less than fourfold range between the minimum (3.4 nM) and maximum (11.2 nM) IC(50) values. SCH 727965 demonstrated an activity pattern consistent with cytotoxicity for most of the cell lines. Forty-three xenograft models were studied and SCH 727965 induced significant delays in event free survival distribution compared to control in 23 of 36 (64%) evaluable solid tumor xenografts and in 3 of 7 ALL xenografts. SCH 727965 did not induce objective responses in the solid tumor panels and the best response observed was stable disease for one osteosarcoma xenograft. In the leukemia panel, there were two objective responses with a complete response observed in a single xenograft. CONCLUSIONS:SCH 727965 shows an interesting pattern of activity suggesting its potential applicability against selected childhood cancers, particularly leukemias.

journal_name

Pediatr Blood Cancer

journal_title

Pediatric blood & cancer

authors

Gorlick R,Kolb EA,Houghton PJ,Morton CL,Neale G,Keir ST,Carol H,Lock R,Phelps D,Kang MH,Reynolds CP,Maris JM,Billups C,Smith MA

doi

10.1002/pbc.24073

subject

Has Abstract

pub_date

2012-12-15 00:00:00

pages

1266-74

issue

7

eissn

1545-5009

issn

1545-5017

journal_volume

59

pub_type

杂志文章
  • The strange case of the lost NRAS mutation in a child with juvenile myelomonocytic leukemia.

    abstract::Juvenile myelomonocytic leukemia (JMML) is a rare myelodysplastic/myeloproliferative disorder of early childhood characterized by mutations of the RAS-RAF-MAP kinase signaling pathway. We report the case of a child with a diagnosis of JMML carrying two mutations of NRAS gene (c.37G>C and c.38G>A) independently occurri...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23401

    authors: De Filippi P,Zecca M,Novara F,Lisini D,Maserati E,Pasquali F,Rosti V,Carlo-Stella C,Zavras N,Cagioni C,Zuffardi O,Pagliara D,Danesino C,Locatelli F

    更新日期:2012-09-01 00:00:00

  • A meta-analysis of MTHFR C677T and A1298C polymorphisms and risk of acute lymphoblastic leukemia in children.

    abstract:BACKGROUND:Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms have been implicated in childhood acute lymphoblastic leukemia (ALL) risk, but previously published studies were inconsistent and recent meta-analyses were not adequate. PROCEDURES:In a meta-analysis of 21 publications with 4,706 cas...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,meta分析,评审

    doi:10.1002/pbc.23137

    authors: Yan J,Yin M,Dreyer ZE,Scheurer ME,Kamdar K,Wei Q,Okcu MF

    更新日期:2012-04-01 00:00:00

  • Clinical and hematological features of homozygous hemoglobin O-Arab [beta 121 Glu → Lys].

    abstract::Hemoglobin O-Arab [Beta 121 Glu → Lys] (Hb O-Arab) is a rare abnormal hemoglobin (Hb) whose clinical and hematological features have been described in adults but not in children. We report three children, 9, 12, and 36 months of age, with homozygous Hb O-Arab and assess the value of supplementary folic acid as treatme...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24414

    authors: Dror S

    更新日期:2013-03-01 00:00:00

  • Palliative radiotherapy for pediatric patients: Parental perceptions of indication, intent, and outcomes.

    abstract:OBJECTIVES:Palliative radiation therapy (pRT) is often used to improve quality of life for pediatric patients. Though palliative doses are generally lower than those for cure, pRT may still introduce undesirable effects. The decision to pursue additional therapy for a child may be challenging and depends on parents' kn...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28003

    authors: Lee BK,Boyle PJ,Zaslowe-Dude C,Wolfe J,Marcus KJ

    更新日期:2020-01-01 00:00:00

  • Familial retinoblastoma in developing countries.

    abstract:BACKGROUND:Although screening for familial retinoblastoma has been shown to be beneficial we suspected that such screening programs may be less than optimal in developing countries (DC). METHODS:Retrospective cohort study comparing patients with familial retinoblastoma from five centers in DC (Argentina, Brazil, Turke...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21970

    authors: Chantada GL,Dunkel IJ,Qaddoumi I,Antoneli CB,Totah A,Canturk S,Nawaiseh I,Fandiño A,Pífano I,Peksayar G,Ribeiro KB,Abramson DH

    更新日期:2009-09-01 00:00:00

  • Prolactinoma as the first manifestation of Gardner's syndrome.

    abstract::Familial adenomatous polyposis (FAP) is an inherited condition causing numerous adenomatous colorectal polyps and a markedly elevated risk of colon cancer. FAP may be associated with various extracolonic manifestations such as desmoid fibromatosis and osteomas (termed Gardner's syndrome) and brain tumors, usually medu...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.20985

    authors: Goodin GS,McCarville MB,Thibodeau SN,Skapek SX,Khoury JD,Spunt SL

    更新日期:2008-02-01 00:00:00

  • Malnutrition and neutropenia in children treated for Burkitt lymphoma in Malawi.

    abstract:BACKGROUND:Infection in neutropenic children is a major cause of morbidity and mortality in children treated for cancer. In developing countries, children with cancer are often malnourished at diagnosis. In Blantyre, Malawi, children with Burkitt lymphoma are treated with a local protocol with limited toxicity. The aim...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22032

    authors: Israëls T,van de Wetering MD,Hesseling P,van Geloven N,Caron HN,Molyneux EM

    更新日期:2009-07-01 00:00:00

  • Validation of the school age self-administered pediatric bleeding questionnaire (Self-PBQ) in children aged 8-12 years.

    abstract:BACKGROUND:In the pediatric population, pathologic bleeding is often challenging to identify. The pediatric bleeding questionnaire (PBQ) was developed as a screening tool for von Willebrand disease (VWD) but was designed to be self-completed by children above 12 years of age. The study objective was to determine whethe...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27709

    authors: Bui J,Martyres D,James PD,Grabell J,Wu J,Steele M,Silva M,Rand ML,Blanchette VS,Barrowman N,Klaassen RJ

    更新日期:2019-06-01 00:00:00

  • Young siblings of children with cancer deserve care and a personalized approach.

    abstract::The youngest siblings may be both emotionally vulnerable and often neglected members of the family of a childhood cancer patient. The prompt identification of signs of distress in these subjects allows trained caregivers to intervene with personalized, age-appropriate, attention, and care. A narrative approach, based ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21056

    authors: Massimo LM,Wiley TJ

    更新日期:2008-03-01 00:00:00

  • Long-term results of the AIEOP LNH-97 protocol for childhood lymphoblastic lymphoma.

    abstract:BACKGROUND:Treatment intensification was considered a suitable strategy to increase the cure rate of lymphoblastic lymphoma (LBL) in children. PROCEDURE:The AIEOP LNH-97 trial was run between 1997 and 2007 for newly diagnosed LBL in patients aged less than 18 years. Treatment schedule was based on the previous, LSA2-L...

    journal_title:Pediatric blood & cancer

    pub_type: 临床试验,杂志文章

    doi:10.1002/pbc.25469

    authors: Pillon M,Aricò M,Mussolin L,Carraro E,Conter V,Sala A,Buffardi S,Garaventa A,D'Angelo P,Lo Nigro L,Santoro N,Piglione M,Lombardi A,Porta F,Cesaro S,Moleti ML,Casale F,Mura R,d'Amore ES,Basso G,Rosolen A

    更新日期:2015-08-01 00:00:00

  • Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut.

    abstract::Infliximab-daclizumab was used to treat acute and chronic liver and gut graft-versus-host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.20648

    authors: Rodriguez V,Anderson PM,Trotz BA,Arndt CA,Allen JA,Khan SP

    更新日期:2007-08-01 00:00:00

  • Fludarabine-based reduced toxicity yet myeloablative conditioning is effective and safe particularly in patients with high-risk thalassemia undergoing allogeneic transplantation.

    abstract:INTRODUCTION:Thalassemia major (TM) is an inherited disorder caused by ineffective erythropoiesis. At the present time, allogeneic stem cell transplantation (allo-SCT) is a curative option. Conventional busulfan and cyclophosphamide based myeloablative conditioning regimens are limited by increased toxicity, especially...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.27312

    authors: Sheth V,Grisariu S,Avni B,Stepensky P,Ashkenazi M,Shapira MY,Or R

    更新日期:2018-11-01 00:00:00

  • Childhood cancer survivorship and late effects: The landscape in India in 2020.

    abstract::Survivorship care is a major area of focus in the holistic management of childhood cancer with current knowledge and information almost exclusively from high-income countries. In this review, we summarize the state of scientific knowledge, service delivery, advocacy initiatives, and research efforts in this field in I...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.28556

    authors: Arora RS,Arora PR,Seth R,Sharma S,Kumar C,Dhamankar V,Kurkure P,Prasad M

    更新日期:2020-09-01 00:00:00

  • The Bt-DUX: development of a subjective measure of health-related quality of life in patients who underwent surgery for lower extremity malignant bone tumor.

    abstract:BACKGROUND:To examine the practical applicability, internal consistency, and validity of the Bt-DUX, a disease-specific Health Related Quality of Life (HRQoL) instrument. The Bt-Dux was developed to examine patients' individual values of their life after a malignant bone tumor of the lower extremity at four domains (co...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1002/pbc.22078

    authors: Bekkering WP,Vlieland TP,Koopman HM,Schaap GR,Schreuder HW,Beishuizen A,Tissing WJ,Hoogerbrugge PM,Anninga JK,Taminiau AH

    更新日期:2009-09-01 00:00:00

  • Risk factors for umbilical venous catheter-associated thrombosis in very low birth weight infants.

    abstract:BACKGROUND:Thrombosis in neonates is a rare but serious occurrence, usually associated with central catheterization. The objective of this study was to investigate the risk factors associated with catheter related thrombosis in very low birth weight (VLBW) infants. PROCEDURE:The present retrospective study was perform...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21714

    authors: Narang S,Roy J,Stevens TP,Butler-O'Hara M,Mullen CA,D'Angio CT

    更新日期:2009-01-01 00:00:00

  • Intensity of CNS treatment for pediatric cancer: prediction of social outcomes in survivors.

    abstract:PURPOSE:To evaluate the association of central nervous system (CNS) treatment intensity and the social functioning of children who have completed treatment for leukemia, lymphoma, and solid tumors outside the CNS. Furthermore, we expected that these associations would be moderated by child age at diagnosis and gender. ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21062

    authors: Vannatta K,Gerhardt CA,Wells RJ,Noll RB

    更新日期:2007-10-15 00:00:00

  • Neuropsychological function in children with hemophilia: A review of the Hemophilia Growth and Development Study and introduction of the current eTHINK study.

    abstract::Almost all of what is known about neurologic and cognitive development in hemophilia derives from the Hemophilia Growth and Development Study, conducted during an era when treatment regimens and comorbidities differed significantly from the current environment. Results suggested hemophilia and human immunodeficiency v...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.28004

    authors: Buranahirun C,Walsh KS,Mrakotsky C,Croteau SE,Rajpurkar M,Kearney S,Hannemann C,Wilkening GN,Shapiro KA,Cooper DL

    更新日期:2020-01-01 00:00:00

  • Practical recommendations for the management of children with endemic Burkitt lymphoma (BL) in a resource limited setting.

    abstract::Treatment recommendations for endemic Burkitt lymphoma (BL) in settings with only minimum requirements for curative treatment (PODC setting 1) are described. The reported cure rate for endemic BL is usually <50%. Facilities within setting 1 differ. Three treatment schedules are proposed based on: (1) when accurate sta...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,实务指引

    doi:10.1002/pbc.24407

    authors: Hesseling P,Israels T,Harif M,Chantada G,Molyneux E,Pediatric Oncology in Developing Countries.

    更新日期:2013-03-01 00:00:00

  • Impact of Whole-Body Radiation Dose on Response and Toxicity in Patients With Neuroblastoma After Therapy With 131 I-Metaiodobenzylguanidine (MIBG).

    abstract:BACKGROUND:(131) I-metaiodobenzylguanidine ((131) I-MIBG) is a targeted radiopharmaceutical for patients with neuroblastoma. Despite its tumor-specific uptake, the treatment with (131) I-MIBG results in whole-body radiation exposure. Our aim was to correlate whole-body radiation dose (WBD) from (131) I-MIBG with tumor ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25816

    authors: Trieu M,DuBois SG,Pon E,Nardo L,Hawkins RA,Marachelian A,Twist CJ,Park JR,Matthay KK

    更新日期:2016-03-01 00:00:00

  • Childhood cancer in Africa.

    abstract::The majority of children with cancer live in low- and middle-income countries (LMICs) with little or no access to cancer treatment. The purpose of the paper is to describe the current status of childhood cancer treatment in Africa, as documented in publications, dedicated websites and information collected through sur...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章,评审

    doi:10.1002/pbc.24845

    authors: Kruger M,Hendricks M,Davidson A,Stefan CD,van Eyssen AL,Uys R,van Zyl A,Hesseling P

    更新日期:2014-04-01 00:00:00

  • Caregiver and health care provider preferences of nutritional support in a hematopoietic stem cell transplant unit.

    abstract:BACKGROUND:Many pediatric oncology patients undergoing hematopoietic stem cell transplantation (HSCT) require nutritional support (NS) because of their inability to consume adequate caloric intake enough calories orally. Although NS can be provided either enteraly (EN) or parenteraly (PN), EN is the preferred method of...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.25473

    authors: Williams-Hooker R,Adams M,Havrilla DA,Leung W,Roach RR,Mosby TT

    更新日期:2015-08-01 00:00:00

  • Career burnout among pediatric oncologists.

    abstract:BACKGROUND:Burnout is a work-related syndrome consisting of emotional exhaustion, depersonalization, and diminished feelings of personal accomplishment. Physicians who care for patients with life-threatening illnesses are at high risk for developing burnout. This survey evaluates the prevalence of burnout among pediatr...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.23121

    authors: Roth M,Morrone K,Moody K,Kim M,Wang D,Moadel A,Levy A

    更新日期:2011-12-15 00:00:00

  • Discrepancies between F-18-FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosis.

    abstract:BACKGROUND:Accurate risk stratification of Langerhans cell histiocytosis (LCH) is essential as management can range from conservative in single system, low risk for central nervous system (CNS) involvement lesions to intensive chemotherapy for multisystem or high-risk disease. Additionally, being able to differentiate ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28891

    authors: Ferrell J,Sharp S,Kumar A,Jordan M,Picarsic J,Nelson A

    更新日期:2021-01-14 00:00:00

  • Comparison of gallium and PET scans at diagnosis and follow-up of pediatric patients with Hodgkin lymphoma.

    abstract:BACKGROUND:Positron emission tomography (PET) and gallium scans facilitate diagnosis and staging, evaluation of response to therapy, and monitoring for relapse in Hodgkin lymphoma (HL), but have not been compared in pediatric HL. PROCEDURE:We performed concurrent PET and gallium scans on 44 pediatric HL patients at di...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.21574

    authors: Hines-Thomas M,Kaste SC,Hudson MM,Howard SC,Liu WA,Wu J,Kun LE,Shulkin BL,Krasin MJ,Metzger ML

    更新日期:2008-08-01 00:00:00

  • Chronic lymphocytic leukemia in a child: a challenging diagnosis in pediatric oncology practice.

    abstract::Chronic lymphocytic leukemia/lymphoma (CLL) is an extremely rare disease during childhood. We report a 16-year-old female who presented with lymphadenopathies and she was diagnosed as T cell lymphoblastic lymphoma. Her chemotherapy response was minimal and clinical findings were unusual. Therefore, her biopsy specimen...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24865

    authors: Demir HA,Bayhan T,Üner A,Kurtulan O,Karakuş E,Emir S,Özyörük D,Ceylaner S

    更新日期:2014-05-01 00:00:00

  • Treatment and outcome of patients with thoracic tumors of the Ewing sarcoma family: A report from the Cooperative Weichteilsarkom Studiengruppe CWS-81, -86, -91, -96, and -2002P trials.

    abstract:BACKGROUND:Ewing tumors are the most frequent malignant tumors of the chest wall in children and young adults. Surgical management of these tumors can be challenging. Optimal local control remains controversial. The aim of this study was to analyze treatment, outcome, and surgical procedures in patients with thoracic t...

    journal_title:Pediatric blood & cancer

    pub_type: 更正并重新发布的文章,杂志文章

    doi:10.1002/pbc.27884

    authors: Seitz G,Urla C,Sparber-Sauer M,Schuck A,Vokuhl C,Blank B,Klingebiel T,Kazanowska B,Fuchs J,Koscielniak E

    更新日期:2019-08-01 00:00:00

  • Glucocorticoid-Induced Proliferation in Untreated Pediatric Acute Myeloid Leukemic Blasts.

    abstract::We evaluated the in vitro glucocorticoid (GC) responsiveness of 117 pediatric acute myeloid leukemia cells by considering GC resistance, GC-induced proliferation, and GC-induced differentiation. None of the samples was highly GC sensitive, and only 15% were intermediately sensitive. GC-induced differentiation was not ...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.26011

    authors: Klein K,Haarman EG,de Haas V,Zwaan ChM,Creutzig U,Kaspers GL

    更新日期:2016-08-01 00:00:00

  • Internet-delivered insomnia intervention improves sleep and quality of life for adolescent and young adult cancer survivors.

    abstract:BACKGROUND:Insomnia is common among adolescent and young adult (AYA) cancer survivors. Cognitive-behavioral therapy for insomnia (CBT-I) is considered the gold standard treatment. Standard CBT-I was designed for adults and not adapted to the unique medical, psychosocial, and developmental needs of AYA cancer survivors,...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.28506

    authors: Zhou ES,Recklitis CJ

    更新日期:2020-09-01 00:00:00

  • Information provision and information needs in adult survivors of childhood cancer.

    abstract:BACKGROUND:Knowledge about their past medical history is central for childhood cancer survivors to ensure informed decisions in their health management. Knowledge about information provision and information needs in this population is still scarce. We thus aimed to assess: (1) the information survivors reported to have...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.24762

    authors: Gianinazzi ME,Essig S,Rueegg CS,von der Weid NX,Brazzola P,Kuehni CE,Michel G,Swiss Paediatric Oncology Group (SPOG).

    更新日期:2014-02-01 00:00:00

  • Initial testing (stage 1) of the kinesin spindle protein inhibitor ispinesib by the pediatric preclinical testing program.

    abstract:BACKGROUND:Ispinesib is a highly specific inhibitor of kinesin spindle protein (KSP, HsEg5), a mitotic kinesin required for separation of the spindle poles. Here we report the activity of ispinesib against the in vitro and in vivo panels of the Pediatric Preclinical Testing Program (PPTP). PROCEDURES:Ispinesib was tes...

    journal_title:Pediatric blood & cancer

    pub_type: 杂志文章

    doi:10.1002/pbc.22056

    authors: Carol H,Lock R,Houghton PJ,Morton CL,Kolb EA,Gorlick R,Reynolds CP,Maris JM,Keir ST,Billups CA,Smith MA

    更新日期:2009-12-15 00:00:00